Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai hopes the launch of its first-in-class anti-epileptic drug Fycompa in Britain and other European markets will help offset revenues lost after its Aricept Alzheimer’s therapy went off patent in the region earlier this year, and signal a new phase of growth for the Japanese company.